INMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
INMD is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock lacks a clear bullish technical setup, has no recent catalyst from news, and the latest analyst changes show mixed but slightly cautious sentiment. Since there is no AI Stock Picker or SwingMax buy signal today, and the price is trading near short-term resistance while the trend remains weak, the better call is to hold and wait for a cleaner entry.
Pre-market price is 13.95, down 0.71%, while the broad market is slightly positive. The chart is still technically weak: MACD histogram is negative, RSI_6 is neutral at 59.45, and moving averages remain bearish with SMA_200 > SMA_20 > SMA_5. Key levels show pivot at 13.911, resistance at 14.10 and 14.217, and support at 13.722 and 13.605. Price is sitting just below near-term resistance, so upside follow-through is not confirmed. The short-term pattern data also suggests weakness over the next week.
["Barclays kept an Overweight rating, which shows some continued bullish belief in the business.", "Options flow today is call-heavy, with put-call volume ratio at 0.17.", "Longer-term monthly pattern estimate suggests a possible 3.09% gain over the next month."]
["Baird cut its price target to $14 from $17 and kept Neutral, citing margin pressures and the shift to Lasers.", "No news in the recent week, so there is no clear event-driven catalyst.", "Technical trend remains bearish with SMA_200 > SMA_20 > SMA_5 and negative MACD histogram.", "Pre-market price is already near resistance, limiting near-term upside.", "Hedge funds and insiders are both neutral with no meaningful buying signal.", "No recent congress trading activity reported."]
No usable latest-quarter financial snapshot was provided because of a data error, so a detailed quarter-by-quarter financial assessment is not available. Based on the analyst commentary, the most recent quarter appears to have shown margin pressure, especially tied to the company’s move toward Lasers. Because the latest quarter season was Q1, the available financial read is more cautionary than growth-oriented.
Analyst sentiment is mixed but leaning cautious. Baird lowered its target to $14 from $17 and stayed Neutral after Q1 results, pointing to accelerating margin pressure. Barclays also trimmed its target to $19 from $21 but remained Overweight. Overall, Wall Street appears split: one camp sees valuation and business pressure, while another still sees upside potential, but the target cuts suggest fading conviction in the near term.
